{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:09:00Z","timestamp":1778728140646,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["Sponsorship for this study was funded by UCB. Funding by UCB was in accordance with Good Publication Practice guidelines (http:\/\/www.ismpp.org\/gpp3). UCB had a role in the study design"],"award-info":[{"award-number":["Sponsorship for this study was funded by UCB. Funding by UCB was in accordance with Good Publication Practice guidelines (http:\/\/www.ismpp.org\/gpp3). UCB had a role in the study design"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["collection"],"award-info":[{"award-number":["collection"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["analysis"],"award-info":[{"award-number":["analysis"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["interpretation of the data"],"award-info":[{"award-number":["interpretation of the data"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["manuscript review"],"award-info":[{"award-number":["manuscript review"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["the decision to submit the manuscript for publication. Publication of this article was contingent upon approval by UCB."],"award-info":[{"award-number":["the decision to submit the manuscript for publication. Publication of this article was contingent upon approval by UCB."]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03216-5","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:27:23Z","timestamp":1747898843000},"page":"3400-3418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9936-5865","authenticated-orcid":false,"given":"Helena","family":"Roque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander Rieem","family":"Dun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scarlette","family":"Kienzle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Welby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Ab\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"7","key":"3216_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","volume":"23","author":"V Strand","year":"2017","unstructured":"Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383\u201391.","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"3216_CR2","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3216_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42003-023-04743-z","volume":"6","author":"F Tavasolian","year":"2023","unstructured":"Tavasolian F, Inman RD. Biology and therapeutic potential of mesenchymal stem cell extracellular vesicles in axial spondyloarthritis. Commun Biol. 2023;6(1):413.","journal-title":"Commun Biol"},{"key":"3216_CR4","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/rheumatology\/keae198","volume":"63","author":"S Lembke","year":"2024","unstructured":"Lembke S, Macfarlane GJ, Jones GT. The worldwide prevalence of psoriatic arthritis\u2014a systematic review and meta-analysis. Rheumatology. 2024;63:3211\u201320.","journal-title":"Rheumatology"},{"key":"3216_CR5","unstructured":"The burden of axial spondyloarthritis: a global patient perspective: International Map of Axial Spondyloarthritis (IMAS). 2024 [Accessed 2 Oct 2024]. https:\/\/asif.info\/wp-content\/uploads\/2024\/01\/ASIF-IMAS-global-report-FINAL-Jan-2024-4.pdf."},{"key":"3216_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110646","volume":"122","author":"W Gao","year":"2023","unstructured":"Gao W, Wang Z, Li W, Li Y, Liu M. Biomarkers and biologics related with psoriasis and psoriatic arthritis. Int Immunopharmacol. 2023;122:110646.","journal-title":"Int Immunopharmacol"},{"issue":"21","key":"3216_CR7","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.3390\/ijms21218125","volume":"21","author":"CH Tang","year":"2020","unstructured":"Tang CH. Research of pathogenesis and novel therapeutics in arthritis 2.0. Int J Mol Sci. 2020;21(21):8125.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3216_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3216_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3216_CR10","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/1744666X.2024.2384705","volume":"20","author":"F Kharouf","year":"2024","unstructured":"Kharouf F, Gladman DD. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies. Expert Rev Clin Immunol. 2024;20(11):1381\u2013400.","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 1","key":"3216_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/annrheumdis-2021-eular.2155","volume":"80","author":"A Regierer","year":"2021","unstructured":"Regierer A, Wei\u00df A, Poddubnyy D, et al. POS0296 dosing of BDMARDS in AXSPA and PSA in a real world setting. Ann Rheum Dis. 2021;80(Suppl 1):373.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3216_CR12","doi-asserted-by":"publisher","first-page":"e002837","DOI":"10.1136\/rmdopen-2022-002837","volume":"9","author":"AC Regierer","year":"2023","unstructured":"Regierer AC, Wei\u00df A, Proft F, et al. Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA. RMD Open. 2023;9(1):e002837.","journal-title":"RMD Open"},{"key":"3216_CR13","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12325-020-01522-8","volume":"38","author":"C Grellmann","year":"2021","unstructured":"Grellmann C, Dombrowsky W, Fabricius V, Suruki R, Sheahan A, Joeres L. Epidemiology and treatment of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis in Germany: a real-world evidence study. Adv Ther. 2021;38:366\u201385.","journal-title":"Adv Ther"},{"issue":"6","key":"3216_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3899\/jrheum.221139","volume":"50","author":"S Exarchou","year":"2023","unstructured":"Exarchou S, Wallman JK, Di Giuseppe D, et al. The national prevalence of clinically diagnosed psoriatic arthritis in Sweden in 2017. J Rheumatol. 2023;50(6):781\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"3216_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3216_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/rheumatology\/keaa448","volume":"60","author":"L Pina Vegas","year":"2021","unstructured":"Pina Vegas L, Sbidian E, Penso L, Claudepierre P. Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database. Rheumatology. 2021;60(3):1243\u201351.","journal-title":"Rheumatology"},{"key":"3216_CR17","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40744-021-00344-6","volume":"8","author":"T Hunter","year":"2021","unstructured":"Hunter T, Nguyen C, Birt J, et al. Pain medication and corticosteroid use in ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis in the United States: a retrospective observational study. Rheumatol Ther. 2021;8:1371\u201382.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"3216_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/03009742.2021.1997436","volume":"52","author":"A Kerola","year":"2023","unstructured":"Kerola A, Rollefstad S, Kazemi A, et al. Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents. Scand J Rheumatol. 2023;52(1):42\u201350.","journal-title":"Scand J Rheumatol"},{"issue":"10","key":"3216_CR19","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1007\/s12325-023-02558-2","volume":"40","author":"S Hopson","year":"2023","unstructured":"Hopson S, Gibbs LR, Syed S, Low R, McClung L, Beaty S. Treatment patterns and healthcare resource utilization among newly diagnosed psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa patients with past diagnosis of an inflammatory condition: a retrospective cohort analysis of claims data in the United States. Adv Ther. 2023;40(10):4358\u201376.","journal-title":"Adv Ther"},{"issue":"Suppl 2","key":"3216_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00393-021-00971-y","volume":"80","author":"K Albrecht","year":"2021","unstructured":"Albrecht K, Marschall U, Callhoff J. Prescription of analgesics in patients with rheumatic diseases in Germany: a claims data analysis. Z Rheumatol. 2021;80(Suppl 2):68.","journal-title":"Z Rheumatol"},{"key":"3216_CR21","volume-title":"S3 guidelines on long-term opioid treatment in non-cancer pain: recommendations for opioid use in clinical rheumatology","author":"M Krasselt","year":"2016","unstructured":"Krasselt M, H\u00e4user W, Petzke F, Baerwald C. S3 guidelines on long-term opioid treatment in non-cancer pain: recommendations for opioid use in clinical rheumatology. Berlin: Springer; 2016."},{"key":"3216_CR22","volume-title":"Riktlinjer f\u00f6r l\u00e4kemedelsbehandling vid axial spondylartrit och psoriasisartrit 2024","author":"Swedish Society for Rheumatology","year":"2024","unstructured":"Swedish Society for Rheumatology. Riktlinjer f\u00f6r l\u00e4kemedelsbehandling vid axial spondylartrit och psoriasisartrit 2024. Malm\u00f6: Swedish Society for Rheumatology; 2024."},{"issue":"7","key":"3216_CR23","first-page":"1092","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A, Altenburg A, Augustin M, et al. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm\u2013Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidit\u00e4t. J Dtsch Dermatol Ges. 2021;19(7):1092\u2013117.","journal-title":"J Dtsch Dermatol Ges"},{"key":"3216_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00393-019-0670-3","volume":"78","author":"U Kiltz","year":"2019","unstructured":"Kiltz U, Braun J, Becker A, et al. Long version on the S3 guidelines for axial spondyloarthritis including Bechterew\u2019s disease and early forms, update 2019: evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations. Z Rheumatol. 2019;78:3\u201364.","journal-title":"Z Rheumatol"},{"issue":"6","key":"3216_CR25","first-page":"934","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A, Altenburg A, Augustin M, et al. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm\u2013Teil 1: Therapieziele und Therapieempfehlungen. J Dtsch Dermatol Ges. 2021;19(6):934\u201351.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"3216_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jbspin.2017.11.001","volume":"85","author":"J Schemoul","year":"2018","unstructured":"Schemoul J, Poulain C, Claudepierre P. Treatment strategies for psoriatic arthritis. Jt Bone Spine. 2018;85(5):537\u201344.","journal-title":"Jt Bone Spine"},{"issue":"Suppl4","key":"3216_CR27","doi-asserted-by":"publisher","first-page":"iv47","DOI":"10.1093\/rheumatology\/keaa246","volume":"59","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(Suppl4):iv47\u201357.","journal-title":"Rheumatology (Oxford)"},{"issue":"10136","key":"3216_CR28","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","volume":"391","author":"F Van den Bosch","year":"2018","unstructured":"Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018;391(10136):2285\u201394.","journal-title":"Lancet"},{"issue":"4","key":"3216_CR29","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40744-021-00365-1","volume":"8","author":"W Saalfeld","year":"2021","unstructured":"Saalfeld W, Mixon AM, Zelie J, Lydon EJ. Differentiating psoriatic arthritis from osteoarthritis and rheumatoid arthritis: a narrative review and guide for advanced practice providers. Rheumatol Ther. 2021;8(4):1493\u2013517.","journal-title":"Rheumatol Ther"},{"issue":"4","key":"3216_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.rdc.2015.07.004","volume":"41","author":"PS Helliwell","year":"2015","unstructured":"Helliwell PS, Ruderman EM. Natural history, prognosis, and socioeconomic aspects of psoriatic arthritis. Rheum Dis Clin. 2015;41(4):581\u201391.","journal-title":"Rheum Dis Clin"},{"key":"3216_CR31","unstructured":"De Forskande L\u00e4kemedelsf\u00f6retagen (LIF). Cosentyx (Sekukinumab)\u2014summary of product characteristics. Dosing: FASS database; 2025."},{"key":"3216_CR32","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh). Therapy with Secukinumab: practical information for physicians. DGRh Guidelines; 2024. p. 1\u20132."},{"key":"3216_CR33","unstructured":"De Forskande L\u00e4kemedelsf\u00f6retagen (LIF). Tremfya (Guselkumab)\u2014summary of product characteristics. Dosing: FASS database; 2022."},{"key":"3216_CR34","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh). Therapy with Guselkumab: practical information for physicians. DGRh Guidelines; 2022."},{"key":"3216_CR35","unstructured":"De Forskande L\u00e4kemedelsf\u00f6retagen (LIF). Taltz (Ixekizumab)\u2014summary of product characteristics. dosing. FASS Database; 2023."},{"key":"3216_CR36","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie (DGRh). Therapy with Ixekizumab: practical information for physicians. DGRh Guidelines; 2024. p. 1\u20132."},{"key":"3216_CR37","unstructured":"EMA. Cosentyx (secukinumab) European public assessment report: summary of product characteristics. European Medicines Agency; 2021."},{"key":"3216_CR38","unstructured":"EMA. Tremfya (guselkumab) European public assessment report: summary of product characteristics. European Medicines Agency; 2021."},{"key":"3216_CR39","unstructured":"EMA. Taltz (ixekizumab) European public assessment report: summary of product characteristics. European Medicines Agency; 2021."},{"issue":"11","key":"3216_CR40","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1111\/ced.15288","volume":"47","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Freilich J, Stelmaszuk MN, et al. Real-world dose adjustments of biologic treatments in psoriasis and their economic impact: a Swedish national population study. Clin Exp Dermatol. 2022;47(11):1968\u201375.","journal-title":"Clin Exp Dermatol"},{"key":"3216_CR41","volume-title":"SAT0428 impact of dose escalation of secukinumab in patients with psoriatic arthritis in real-world setting","author":"MM Lopez","year":"2020","unstructured":"Lopez MM, Joven-Ib\u00e1\u00f1ez B, Pablos J. SAT0428 impact of dose escalation of secukinumab in patients with psoriatic arthritis in real-world setting. London: BMJ; 2020."},{"issue":"11","key":"3216_CR42","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1161\/CIRCRESAHA.115.306883","volume":"118","author":"FB Ortega","year":"2016","unstructured":"Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118(11):1752\u201370.","journal-title":"Circ Res"},{"issue":"26","key":"3216_CR43","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"3216_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00296-015-3348-4","volume":"36","author":"R Lyu","year":"2016","unstructured":"Lyu R, Govoni M, Ding Q, et al. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol Int. 2016;36(1):143\u201353.","journal-title":"Rheumatol Int"},{"key":"3216_CR45","doi-asserted-by":"publisher","unstructured":"Robertson J, Tindell A, Crosbie D, Siebert S. 190\u00b0 Real-world experience of secukinumab for psoriatic arthritis and axial spondyloarthritis. Rheumatology. 2018;57(suppl_3):key075.414. https:\/\/doi.org\/10.1093\/rheumatology\/key075.414.","DOI":"10.1093\/rheumatology\/key075.414"},{"key":"3216_CR46","doi-asserted-by":"publisher","first-page":"1156557","DOI":"10.3389\/fmed.2023.1156557","volume":"10","author":"F Sivera","year":"2023","unstructured":"Sivera F, N\u00fa\u00f1ez-Monje V, Campos-Fern\u00e1ndez C, et al. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum. Front Med (Lausanne). 2023;10:1156557.","journal-title":"Front Med (Lausanne)"},{"key":"3216_CR47","doi-asserted-by":"publisher","first-page":"103638","DOI":"10.1016\/j.autrev.2024.103638","volume":"23","author":"F Proft","year":"2024","unstructured":"Proft F, Duran TI, Ghoreschi K, Pleyer U, Siegmund B, Poddubnyy D. Treatment strategies for spondyloarthritis: implementation of precision medicine\u2014or \u201cone size fits all\u201d concept? Autoimmunity Rev. 2024;23:103638.","journal-title":"Autoimmunity Rev"},{"issue":"4","key":"3216_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A. Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol. 2022;18(4):205\u201316.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03216-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:14:45Z","timestamp":1750493685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03216-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3216"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03216-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas Wilke worked for consultancies, including Cytel Inc., GIPAM, GmbH, which undertook projects sponsored by pharmaceutical companies such as UCB. Sarah Welby is currently employed by GlaxoSmithKline Vaccines. The positions and opinions presented in this article reflect the work Sarah carried out during her employment at UCB, when the study was conducted and are not intended to represent the views or scientific works of GlaxoSmithKline. She is an employee and shareholder of GlaxoSmithKline. She declares no financial or non-financial relationships and activities and no conflicts of interest. Jie Song is currently employed by West China Hospital, Sichuan University. The positions and opinions presented in this article reflect the work Jie carried out during her employment at UCB. She declares no competing interests. Alexander Rieem Dun is currently employed by Schain Research. The positions and opinions presented in the article reflect the work Alexander carried out during his employment at Quantify Research. He declares no competing interests. Helena Roque, Alexandra Cooper, Scarlette Kienzle, and Christoph Ab\u00e9 declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the protocol, applicable regulations, and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. The independent ethics committee and institutional review board in Sweden, the Swedish Ethical Review Authority, approved the study protocol and related documents (approval number 2022-05312-01, October 31, 2022). The Swedish Ethical Review Board waived the requirement to obtain any informed consent for this analysis of existing administrative data. Due to the non-interventional, retrospective nature of the analyzed data and because the analysis involved an anonymized dataset, neither ethical review nor informed consent of the patients was required to obtain the German data, in accordance with German national legislation (\u00a7 75 SGB X). As the responsible authority, the involved sickness fund (AOK PLUS) approved the use of the data for the purpose of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}